Neal White, MD
Cardiovascular Disease · Walnut Creek, CANPI 1659301216
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $96,850 of the $135,732 with a category attached, or 71.4%. 33 manufacturers reported payments, led by Johnson & Johnson at 54.5% of the total. Reporting peaked in 2019 at $102,254 and has fallen 99.0% since, to $974 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $360.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$74K
- Portola Pharmaceuticals, LLC$25K
- Medtronic$14K
- AstraZeneca$13K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
- Boston Scientific$2K
- plus $4K from 27 others
Across 31 payments — averaging $6846.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$212K
Across 3 payments — averaging $1728.33 each. An ownership or investment interest held by the physician or an immediate family member.
- Vital Connect, Inc$5K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$96,85071%
- Travel & lodging$25,63919%
- Food & beverage$12,93810%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 89 | $73,964 |
| Portola Pharmaceuticals, LLC | 34 | $24,792 |
| Medtronic(2 entities) | 49 | $13,900 |
| AstraZeneca | 41 | $12,913 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $3,986 |
| Boston Scientific | 20 | $1,714 |
| Edwards Lifesciences | 12 | $947 |
| Abbott | 14 | $887 |
| Novartis | 22 | $510 |
| Biotronik Inc. | 3 | $288 |
| Amgen | 9 | $182 |
| Janssen Scientific Affairs, LLC | 4 | $172 |
| Abiomed | 4 | $169 |
| E.r. Squibb & Sons, L.L.C. | 7 | $160 |
| Shockwave Medical, Inc | 5 | $158 |
| Heartflow, Inc. | 2 | $143 |
| Amarin Pharma, Inc. | 3 | $139 |
| Novo Nordisk | 1 | $116 |
| Boehringer Ingelheim | 6 | $104 |
| Esperion Therapeutics, Inc. | 5 | $101 |
| Merck | 3 | $62 |
| Bayer | 3 | $53 |
| Pfizer | 3 | $43 |
| Cathworks, Inc. | 3 | $37 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Siemens Medical Solutions USA, Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Atricure, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$72,832
- ANDEXXA$24,254
- FARXIGA$12,041
- Resolute$6,175
- LifeVest$3,362
- CoreValve Evolut$1,575
- Edwards SAPIEN 3 Transcatheter Heart Valve$771
- GENERAL - THERAPIES$631
- 3F$482
- HeartMate II LVAS$406
- Azure$364
- WAINUA$253
- Evera$190
- Micra$156
- LUX-Dx Insertable Cardiac Monitor$141
- Claria MRI$136
- Vascepa$132
- LUX-DX$124
- Impella$120
- GENERAL - STRUCTURAL HEART$118
How this compares
$135,732 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 11 | $466,979 |
| EliquisApixaban | 298 | $404,109 |
| XareltoRivaroxaban | 243 | $333,222 |
| Repatha SureclickEvolocumab | 244 | $280,634 |
| EntrestoSacubitril/Valsartan | 81 | $107,681 |
| Praluent PenAlirocumab | 36 | $47,773 |
| MultaqDronedarone Hcl | 24 | $42,405 |
| JardianceEmpagliflozin | 28 | $40,639 |
| FarxigaDapagliflozin Propanediol | 26 | $33,516 |
| BrilintaTicagrelor | 25 | $26,763 |
| Rosuvastatin Calcium | 929 | $20,711 |
| Metoprolol Succinate | 558 | $10,903 |
| Carvedilol ErCarvedilol Phosphate | 13 | $5,873 |
| Ezetimibe | 159 | $5,831 |
| Ranolazine ErRanolazine | 42 | $5,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $43 | $871,088309 claims |
| Johnson & JohnsonXarelto | $73,964 | $333,222243 claims |
| NovartisEntresto | $510 | $107,68181 claims |
| AstraZenecaFarxiga, Brilinta | $12,913 | $60,27951 claims |
| Boehringer IngelheimJardiance | $104 | $40,63928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Walnut Creek
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.